Provided by Tiger Trade Technology Pte. Ltd.

Charles River Laboratories

286.83
-8.1800-2.77%
Post-market: 286.830.00000.00%19:31 EDT
Volume:823.07K
Turnover:238.00M
Market Cap:13.69B
PE:-58.76
High:297.00
Open:291.86
Low:284.61
Close:295.01
52wk High:303.31
52wk Low:146.20
Shares:47.74M
Float Shares:47.20M
Volume Ratio:0.86
T/O Rate:1.74%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.8814
EPS(LYR):-2.9122
ROE:-7.52%
ROA:4.11%
PB:4.82
PE(LYR):-98.49

Loading ...

Charles River Laboratories International Inc. Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Jul 08

Evercore ISI Adjusts Price Target on Charles River Laboratories International to $260 From $220

MT Newswires Live
·
Jul 07

Coda Octopus Appoints Mark Kelly CFO Effective Aug. 3, 2026

Reuters
·
Jul 06

Charles River Laboratories International Inc. Stock Underperforms Wednesday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Jul 02

Charles River Labs Director James C. Foster Disposes of 75,000 Shares Worth $16.88 Million

Reuters
·
Jul 02

Argus Raises Price Target on Charles River Laboratories International to $250 From $200, Maintains Buy Rating

MT Newswires Live
·
Jul 01

Unicycive Therapeutics CRL tied to same vendor deficiency, says B. Riley

TIPRANKS
·
Jun 30

Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)

GlobeNewswire
·
Jun 30

Charles River Laboratories International Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jun 30

Charles River Laboratories International Inc. Stock Underperforms Friday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Jun 27

Lantheus Receives Complete Response Letter from FDA for LNTH-2501 (Ga 68 edotreotide)

GlobeNewswire
·
Jun 27

Charles River Laboratories International Inc. Stock Advances 5.2%, Outperforms Peers

Dow Jones
·
Jun 26

BTIG’s Brisebois Reiterates Buy on Aquestive Therapeutics, Calling Sell-Off Overdone After SPRY Payer Update and Highlighting Limited Scope of FDA CRL for Anaphylm

TIPRANKS
·
Jun 26

Movement Alert|Charles River Laboratories Rises 5.09% in Regular Trading, Morgan Stanley Upgrade and Positive Annual Report Signals Continue to Drive Momentum

Market Focus
·
Jun 25

Tanvex's US Unit Receives FDA Nod for TX05 Cancer Drug Biosimilar; Shares Drop 10%

MT Newswires Live
·
Jun 25

Charles River Laboratories International Inc. Stock Advances 8.3%, Outperforms Peers

Dow Jones
·
Jun 25

Movement Alert|Charles River Laboratories Rises 6.55% in Regular Trading, Morgan Stanley Upgrade and Positive Earnings Conference Signals Drive Rally

Market Focus
·
Jun 24

Charles River Laboratories International Inc. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
Jun 23

Achieve Life Sciences CRL from FDA cites deficiencies at manufacturing facility

TIPRANKS
·
Jun 22

Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA

GlobeNewswire
·
Jun 22